@The_Infinitian
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
→ Embedded. gl | A @Prosperahn company » HQ on Roatán | Building the future of Military. /IPP/ ***Largest Twitter Account*** of 15yrs was Hacked.
Joined April 2019
- Tweets555
- Following5
- Followers44
- Likes1.5K
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
I am towards the end of writing an article about Eli Lilly and its rise and would like to interview some more people about the way pharma generally operates and also Lilly specially and potentially get quotes from them. Would really appreciate if anyone could offer to do it!
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
Montana's Experimental Treatment Review Board reviews treatments once they've cleared Phase 1 safety data.
It doesn't replace Phase 3, or the verdict that can move a stock 60% overnight on someone else's data. But it does change who can act on Phase 1 data, and when, while the bigger trial process is still running, allowing for more data and potentially more biotechs to survive the path until final approval.
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
It starts with eligibility. The treatment has to have completed Phase 1 and meet Montana's safety criteria.
Next, an Experimental Treatment Review Board (ETRB) independently reviews the protocol, the safety data, and the informed consent plan.
Then it moves to a licensed Experimental Treatment Center (ETC), the facility where the actual care happens.
Finally, the decision still comes down to the individual patient and their provider.
Read the full breakdown here ↓
infinitacitytimes.com/p/how-…
John Ternus is absolutely a weak CEO.
It’s roughly 2 weeks since this new role.
Let’s hope he can turn things around.
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
It's official, as of today we have launched the first ever Experimental Treatment Review Board under Montana SB535!
This ETRB consists of 5 highly qualified members who will review treatment protocols for use under Montana's new Right to Try law. Once the ETRB has approved a treatment protocol, it is authorized for use at any Montana licensed Experimental Treatment Clinic.
The ETRB is also responsible for collecting, analyzing, and publishing, both aggregate outcomes and adverse events data.
If you've got a post phase-1 Biotech and you're interested, head to montanaetrb.org to learn more, or DM me here!
Announcing Montana ETRB
Montana opens up for biotech acceleration.
Infinita has formed the first-ever ETRB (experimental treatment review board) under Montana law.
The review board’s role is oversight for access to treatments before FDA approval.
For a $12.5k fee, you can submit a post-phase-1 therapy to our review board (submission link below).
What is a Montana ETRB?
Montana’s model is a major regulatory innovation. National regulators typically review treatments one by one, which causes years-long bottlenecks.
In Montana, registered ETRBs do treatment reviews, licensed specialized clinics (ETCs) provide treatments. The state receives reporting and can take away licenses.
That’s smart regulation. Competitive, efficient, with oversight. That’s what American biotech needs.
First Montana ETRB Members
We are honored to welcome highly esteemed scientists, physicians and bioethicists on the first Montana ETRB:
- Matt Kaeberlein, PhD (@mkaeberlein) - a biologist internationally recognized for research on the basic mechanisms of aging and translational interventions to extend healthspan
- Felipe Sierra, PhD - a biochemist that served as Director of the Division of Aging Biology, NIA/NIH, where he developed the concept of Geroscience.
- Jessica Flanigan, PhD - a bioethicist who is is the Richard L. Morrill Chair in Ethics and Democratic Values at the University of Richmond, where she teaches leadership and healthcare ethics
- Jamie Justice, PhD (@j_n_justice) - is Executive Vice President of the Health Domain at XPRIZE and Executive Director of the XPRIZE Healthspan Prize
- James M. Burke, MD - is a hematologist and oncologist with more than three decades of experience in cancer drug development and patient care
Each review submitted will have to pass their judgement on adequate safety characterization.
What will the ETRB look for?
An ETRB’s legal mandate is safety-only.
Risks need to be disclosed to patients for informed consent properly, and treatments need to have a safety profile equivalent to a successful phase-1 trial.
After that it’s up to the doctor and patient to decide.
ETRB will compete for reputation.
They are free to approve or not approve according to their assessment. If they wanted, they could even ask for efficacy data as a basis for approval.
Our Montana ETRB has a set of governance principles that guide its decisions beyond the legally required minimum floor, as a guide for its decisionsmaking.
Congratulations to Montana
Thanks to the leadership of Sen. Kenneth Bogner (@KennethBogner), Montana now has the most forward looking medical access law in the country in SB 535.
Montana’s department of health and human services (DPHHS) provided a tight and comprehensive set of rules for clinic licenses and review boards.
Montana is becoming a biotech frontier.
Towards Clinical Trial Abundance
The FDA has led the world for decades, gating the largest and most innovative biopharma market in the world. But the US’ competitive advantage is evaporating. Regulators in Australia and China have made clinical trials far more cost- and time-competitive. Patients are going to offshore clinics in Mexico and the Caribbean. High-agency patients like Sid Sijbrandij (@sytses) take matters into their own hands, and use multiple available jurisdictions.
The FDA needs to modernize, and lots of federal efforts to this end are underway. We support federal reforms, however these efforts often fall short or are slow.
Let US states innovate. The states can be as a source of regulatory innovation. In states important learnings can take place, and inform better federal policy.
Montana is leading the charge in biotech. New Hampshire is following suit. Utah, Texas and Florida have opened up to stem cells and many states are improving conditions for individualized treatments.
FDA / HHS should give explicit safe harbor to such responsible state medical access programs, to encourage a regulated market forming vs. gray markets.
How to Get Involved
We’re looking for state and federal policymakers to advance this regulatory innovation, clinicians to be the patient-facing stewards for responsible access, scientific reviewers to partake in ETRB oversight, biotechs to provide their novel treatments to these programs to collect valuable data, and ultimately for patients to benefit from potentially life-saving access.
Get in touch! Mine and @righttotryguys DMs are open
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
Announcing Montana ETRB
Montana opens up for biotech acceleration.
Infinita has formed the first-ever ETRB (experimental treatment review board) under Montana law.
The review board’s role is oversight for access to treatments before FDA approval.
For a $12.5k fee, you can submit a post-phase-1 therapy to our review board (submission link below).
What is a Montana ETRB?
Montana’s model is a major regulatory innovation. National regulators typically review treatments one by one, which causes years-long bottlenecks.
In Montana, registered ETRBs do treatment reviews, licensed specialized clinics (ETCs) provide treatments. The state receives reporting and can take away licenses.
That’s smart regulation. Competitive, efficient, with oversight. That’s what American biotech needs.
First Montana ETRB Members
We are honored to welcome highly esteemed scientists, physicians and bioethicists on the first Montana ETRB:
- Matt Kaeberlein, PhD (@mkaeberlein) - a biologist internationally recognized for research on the basic mechanisms of aging and translational interventions to extend healthspan
- Felipe Sierra, PhD - a biochemist that served as Director of the Division of Aging Biology, NIA/NIH, where he developed the concept of Geroscience.
- Jessica Flanigan, PhD - a bioethicist who is is the Richard L. Morrill Chair in Ethics and Democratic Values at the University of Richmond, where she teaches leadership and healthcare ethics
- Jamie Justice, PhD (@j_n_justice) - is Executive Vice President of the Health Domain at XPRIZE and Executive Director of the XPRIZE Healthspan Prize
- James M. Burke, MD - is a hematologist and oncologist with more than three decades of experience in cancer drug development and patient care
Each review submitted will have to pass their judgement on adequate safety characterization.
What will the ETRB look for?
An ETRB’s legal mandate is safety-only.
Risks need to be disclosed to patients for informed consent properly, and treatments need to have a safety profile equivalent to a successful phase-1 trial.
After that it’s up to the doctor and patient to decide.
ETRB will compete for reputation.
They are free to approve or not approve according to their assessment. If they wanted, they could even ask for efficacy data as a basis for approval.
Our Montana ETRB has a set of governance principles that guide its decisions beyond the legally required minimum floor, as a guide for its decisionsmaking.
Congratulations to Montana
Thanks to the leadership of Sen. Kenneth Bogner (@KennethBogner), Montana now has the most forward looking medical access law in the country in SB 535.
Montana’s department of health and human services (DPHHS) provided a tight and comprehensive set of rules for clinic licenses and review boards.
Montana is becoming a biotech frontier.
Towards Clinical Trial Abundance
The FDA has led the world for decades, gating the largest and most innovative biopharma market in the world. But the US’ competitive advantage is evaporating. Regulators in Australia and China have made clinical trials far more cost- and time-competitive. Patients are going to offshore clinics in Mexico and the Caribbean. High-agency patients like Sid Sijbrandij (@sytses) take matters into their own hands, and use multiple available jurisdictions.
The FDA needs to modernize, and lots of federal efforts to this end are underway. We support federal reforms, however these efforts often fall short or are slow.
Let US states innovate. The states can be as a source of regulatory innovation. In states important learnings can take place, and inform better federal policy.
Montana is leading the charge in biotech. New Hampshire is following suit. Utah, Texas and Florida have opened up to stem cells and many states are improving conditions for individualized treatments.
FDA / HHS should give explicit safe harbor to such responsible state medical access programs, to encourage a regulated market forming vs. gray markets.
How to Get Involved
We’re looking for state and federal policymakers to advance this regulatory innovation, clinicians to be the patient-facing stewards for responsible access, scientific reviewers to partake in ETRB oversight, biotechs to provide their novel treatments to these programs to collect valuable data, and ultimately for patients to benefit from potentially life-saving access.
Get in touch! Mine and @righttotryguys DMs are open
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
Big news - very important milestone in accelerating the regulatory process in the USA. Especially look at the membership - no one can accuse this process of being likely to cut corners! Huge kudos to all involved.
Announcing Montana ETRB
Montana opens up for biotech acceleration.
Infinita has formed the first-ever ETRB (experimental treatment review board) under Montana law.
The review board’s role is oversight for access to treatments before FDA approval.
For a $12.5k fee, you can submit a post-phase-1 therapy to our review board (submission link below).
What is a Montana ETRB?
Montana’s model is a major regulatory innovation. National regulators typically review treatments one by one, which causes years-long bottlenecks.
In Montana, registered ETRBs do treatment reviews, licensed specialized clinics (ETCs) provide treatments. The state receives reporting and can take away licenses.
That’s smart regulation. Competitive, efficient, with oversight. That’s what American biotech needs.
First Montana ETRB Members
We are honored to welcome highly esteemed scientists, physicians and bioethicists on the first Montana ETRB:
- Matt Kaeberlein, PhD (@mkaeberlein) - a biologist internationally recognized for research on the basic mechanisms of aging and translational interventions to extend healthspan
- Felipe Sierra, PhD - a biochemist that served as Director of the Division of Aging Biology, NIA/NIH, where he developed the concept of Geroscience.
- Jessica Flanigan, PhD - a bioethicist who is is the Richard L. Morrill Chair in Ethics and Democratic Values at the University of Richmond, where she teaches leadership and healthcare ethics
- Jamie Justice, PhD (@j_n_justice) - is Executive Vice President of the Health Domain at XPRIZE and Executive Director of the XPRIZE Healthspan Prize
- James M. Burke, MD - is a hematologist and oncologist with more than three decades of experience in cancer drug development and patient care
Each review submitted will have to pass their judgement on adequate safety characterization.
What will the ETRB look for?
An ETRB’s legal mandate is safety-only.
Risks need to be disclosed to patients for informed consent properly, and treatments need to have a safety profile equivalent to a successful phase-1 trial.
After that it’s up to the doctor and patient to decide.
ETRB will compete for reputation.
They are free to approve or not approve according to their assessment. If they wanted, they could even ask for efficacy data as a basis for approval.
Our Montana ETRB has a set of governance principles that guide its decisions beyond the legally required minimum floor, as a guide for its decisionsmaking.
Congratulations to Montana
Thanks to the leadership of Sen. Kenneth Bogner (@KennethBogner), Montana now has the most forward looking medical access law in the country in SB 535.
Montana’s department of health and human services (DPHHS) provided a tight and comprehensive set of rules for clinic licenses and review boards.
Montana is becoming a biotech frontier.
Towards Clinical Trial Abundance
The FDA has led the world for decades, gating the largest and most innovative biopharma market in the world. But the US’ competitive advantage is evaporating. Regulators in Australia and China have made clinical trials far more cost- and time-competitive. Patients are going to offshore clinics in Mexico and the Caribbean. High-agency patients like Sid Sijbrandij (@sytses) take matters into their own hands, and use multiple available jurisdictions.
The FDA needs to modernize, and lots of federal efforts to this end are underway. We support federal reforms, however these efforts often fall short or are slow.
Let US states innovate. The states can be as a source of regulatory innovation. In states important learnings can take place, and inform better federal policy.
Montana is leading the charge in biotech. New Hampshire is following suit. Utah, Texas and Florida have opened up to stem cells and many states are improving conditions for individualized treatments.
FDA / HHS should give explicit safe harbor to such responsible state medical access programs, to encourage a regulated market forming vs. gray markets.
How to Get Involved
We’re looking for state and federal policymakers to advance this regulatory innovation, clinicians to be the patient-facing stewards for responsible access, scientific reviewers to partake in ETRB oversight, biotechs to provide their novel treatments to these programs to collect valuable data, and ultimately for patients to benefit from potentially life-saving access.
Get in touch! Mine and @righttotryguys DMs are open
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
Personal update: I'm taking a leave of absence from YC to join Anthropic. I'll be working with @NotTomBrown on the compute team.
Powerful AI has the potential to improve the life of every human on earth and, as we enter the early stages of recursive self-improvement, availability of compute becomes one of the most important issues to solve.
I'm excited to get started 🚀
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
Your entire SDLC should be automatable with AI agents. But just like there's no one-stop dev workflow, there's no one-stop agent.
That's why we're building amika.dev: infra for every company to build their own software factory, customized to them.
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
Good lessons on managing AI spend. We support a lot of this natively on Databricks with Unity AI Gateway, which makes it easy to analyze and control usage in one place, and it’s also easy to set these up as policies with the open source Omnigent.ai framework.
How to keep AI spend flat while token usage grows exponentially: Not with friction and spend alerts. With better defaults, routing, and caching.
Better Defaults (not Usage Caps) – Engineers can choose any model they want, but defaults matter. We’re experimenting with defaulting to open weight models like GLM 5.2 and Kimi 2.7 through our LLM gateway, while still encouraging engineers to choose the right model for the task. 91% of our employees were never hitting their usage caps, so instead of lowering caps and driving up alerts, we're moving to cheaper defaults. Note that code reviews use a diversity of models, so they can check each other's work.
Better Routing – In our custom harnesses, we preprocess prompts and route to the best model for the job, considering cache hits and model pricing. For instance, you may want a frontier model for planning, but not for execution where they can be overkill. Ultimately, humans shouldn't be choosing models - AI can automate this task.
Better Caching – Cache misses are the easiest way to drive your cost up. All of our requests are cache aware, so we’re reusing a warm cache wherever possible. For example, our cache hit rate went from 5% → 60% in LibreChat once properly implemented.
Keep Context Lean – Start fresh sessions when switching tasks. Scope file context narrowly. Disconnect unused tools. Don't just compact. The goal isn't fewer tokens used, it's fewer tokens wasted.
Better Visibility – Our engineers can use as many tokens as they want, from whatever model they want, but we’ve made usage visible – and the more you spend on AI, the more impact we expect.
The goal isn't to suppress usage. It's to build the infrastructure that makes exponential growth sustainable.
Putting this into practice has cut our AI spend nearly in half, while our token usage continues to grow.
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
We've officially entered the era of "token engineering."
Aka token-efficiency maxxing.
The smartest way to cut your AI spend by 50%+ or more:
A barbell strategy.
First 10% and planning the project: Highest intelligence (Opus/GPT) - this is the most important part
Middle 80% (grunt work): Cheaper, open-sourced model for pure execution
Final 10% and verification: Switch back to the high-intelligence model
I've been doing this for months, and it's hands-down the best way to reduce ridiculous AI spend.
How to keep AI spend flat while token usage grows exponentially: Not with friction and spend alerts. With better defaults, routing, and caching.
Better Defaults (not Usage Caps) – Engineers can choose any model they want, but defaults matter. We’re experimenting with defaulting to open weight models like GLM 5.2 and Kimi 2.7 through our LLM gateway, while still encouraging engineers to choose the right model for the task. 91% of our employees were never hitting their usage caps, so instead of lowering caps and driving up alerts, we're moving to cheaper defaults. Note that code reviews use a diversity of models, so they can check each other's work.
Better Routing – In our custom harnesses, we preprocess prompts and route to the best model for the job, considering cache hits and model pricing. For instance, you may want a frontier model for planning, but not for execution where they can be overkill. Ultimately, humans shouldn't be choosing models - AI can automate this task.
Better Caching – Cache misses are the easiest way to drive your cost up. All of our requests are cache aware, so we’re reusing a warm cache wherever possible. For example, our cache hit rate went from 5% → 60% in LibreChat once properly implemented.
Keep Context Lean – Start fresh sessions when switching tasks. Scope file context narrowly. Disconnect unused tools. Don't just compact. The goal isn't fewer tokens used, it's fewer tokens wasted.
Better Visibility – Our engineers can use as many tokens as they want, from whatever model they want, but we’ve made usage visible – and the more you spend on AI, the more impact we expect.
The goal isn't to suppress usage. It's to build the infrastructure that makes exponential growth sustainable.
Putting this into practice has cut our AI spend nearly in half, while our token usage continues to grow.
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
This post is blowing up.
Many people: “how can you possibly spend this much?! Just use multiple ___ Max plans for $200/mo”
We’re shipping ~30 PRs daily because @HelloUntangle is growing very quickly.
We have a complete software factory on @DevinAI that allows this speed - primarily because it’s cloud-first vs local dev, has visual testing out-of-the box, automated landing with thorough code review-fix loop. This allows for much more effective parallelism.
FYI, we get $5k/mo in credits but we’re still spending another $15k on top.
We’ve actually increased this now and are spending $1k/day for my work.
I think all CEOs will eventually accept that it’s going to cost $2-5k per month per engineer (and eventually all employees because everyone will be using agents for most of their work).
So the agent labs will figure out how to deliver the same number of high quality tokens but for 1/4 the price of frontier-only.
The labs will probably cave as well and realize they need to do proper model routing based on the goal of the thread.
I'm starting to hit $15-20k per month in token spend for engineering - just for myself.
Next month I'll be looking to implement the kinds of things that Brian is doing here at Coinbase.
Most likely switching to GLM 5.2 as default and only using frontier models for harder tasks.
I can probably get that $20k down to <$5k pretty easily.
I'm pretty sure we'll see everyone doing this.
It's just not financially viable to do everything with frontier models
This is another reason I think we'll see people move away from choosing a lab for their harness (CC or Codex) and move their code factories to in-house agents like @tryramp or agent labs like @DevinAI @FactoryAI @cursor_ai @AmpCode
The labs are not incentivized to drive down your token costs
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
Your 2026 Passport Across the Free State!

For more than two decades, people have come to New Hampshire for PorcFest to see what the Free State Project is all about. But during those same two decades, something else has been happening quietly across the Granite State. 1/
Dev @Embeddedđź‘“/PrĂłsperađź“Ť retweeted
The final rant of @PorcFest XXIII: Spontaneous Order, delivered at Man Camp before the Saturday night “Burning of the Porcupine.”
It was a rant against “PorcFest pessimism” and a thank you to all the builders who are keeping the spirit of the festival alive.